ReviewTherapeutic delivery2017
Designing and developing suppository formulations for anti-HIV drug delivery.
Review in Therapeutic delivery, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed.
- A conjoint experiment of three placebo rectal products used with receptive anal sex: results from MTN-035.Journal of the International AIDS Society · 2024Trial
- Assessment of the Radiopacity of Medication in Veterinary Medicine.Veterinary radiology & ultrasound : the official journal of the American College of Veterinary Radiology and the International Veterinary Radiology Association · 2026Article
- Electrospun hydrogel-forming nanofibres embedded in a pH-responsive film for the prevention of sexually transmitted infections.International journal of pharmaceutics: X · 2025Article
- Formulation and Characterization of Etoricoxib Suppositories for the Management of Hemorrhoids.Turkish journal of pharmaceutical sciences · 2025Article
- Development and characterization of formulations based on combinatorial potential of antivirals against genital herpes.Naunyn-Schmiedeberg's archives of pharmacology · 2025Article
- Evaluation of Drug Permeation Enhancement by Using In Vitro and Ex Vivo Models.Pharmaceuticals (Basel, Switzerland) · 2025Review
- The Efficacy of Hybrid Vaginal Ovules for Co-Delivery of Curcumin and Miconazole againstPharmaceutics · 2024Article
- Designing Dual Compartment HIV Prevention Products: Women's Sensory Perceptions and Experiences of Suppositories for Rectal and Vaginal Use.AIDS research and human retroviruses · 2022Article
- Acceptability of a Dapivirine/Placebo Gel Administered Rectally to HIV-1 Seronegative Adults (MTN-026).AIDS and behavior · 2022Article
- Advancements in the Pharmaceutical Applications of Probiotics: Dosage Forms and Formulation Technology.International journal of nanomedicine · 2021Review
- Nanoformulated Eudragit lopinavir and preliminary release of its loaded suppositories.Heliyon · 2020Article
- Transmucosal drug administration as an alternative route in palliative and end-of-life care during the COVID-19 pandemic.Advanced drug delivery reviews · 2020Review
- Innovations in Pediatric Drug Formulations and Administration Technologies for Low Resource Settings.Pharmaceutics · 2019Review
- Physiological and Pharmaceutical Considerations for Rectal Drug Formulations.Frontiers in pharmacology · 2019Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
Abstract
Despite a long history of use for rectal and vaginal drug delivery, the current worldwide market for suppositories is limited primarily due to a lack of user acceptability. Therefore, virtually no rational pharmaceutical development of antiviral suppositories has been performed. However, suppositories offer several advantages over other antiviral dosage forms. Current suppository designs have integrated active pharmaceutical ingredients into existing formulation designs without optimization. As such, emerging suppository development has been focused on improving upon the existing classical design to enhance drug delivery and is poised to open suppository drug delivery to a broader range of drugs, including antiretroviral products. Thus, with continuing research into rational suppository design and development, there is significant potential for antiretroviral suppository drug delivery.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.